Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.37 |
| ▸ | FASN | P49327 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530650 | 0.88 | PAK4 (0.46) | PAK4HRH3GABRA5NAMPTPAK1 | |
| SCHEMBL18530520 | 0.88 | PAK4 (0.43) | PAK4HRH3GABRA5NAMPTPAK1 | |
| SCHEMBL18542112 | 0.84 | PAK4 (0.44) | PAK4HRH3GABRA5NAMPTPAK1 | |
| SCHEMBL18530652 | 0.83 | PAK4 (0.38) | PAK4HRH3GABRA5FASNCNR1 | |
| SCHEMBL18530616 | 0.82 | PAK4 (0.67) | PAK4HRH3GABRA5NAMPTPAK1 | |
| SCHEMBL18530617 | 0.82 | PAK4 (0.67) | PAK4HRH3GABRA5NAMPTPAK1 | |
| SCHEMBL18530614 | 0.79 | PAK4 (0.43) | PAK4HRH3GABRA5HPGDLRRK2 | |
| SCHEMBL18325895 | 0.79 | HRH3 (0.51) | PAK4HRH3GABRA5NAMPTPAK1 | |
| SCHEMBL18530628 | 0.79 | HRH3 (0.37) | PAK4HRH3LRRK2STAT3 | |
| SCHEMBL18530649 | 0.78 | LOXL2 (0.38) | HPGDLRRK2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190218207-A1 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | Karyopharm Therapeutics Inc. | 2019-07-18 | — | — | US | disclosed |
| US-20190218207-A1 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | Karyopharm Therapeutics Inc. | 2019-07-18 | — | — | US | disclosed |
| EP-3337796-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics, Inc. (US) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017031213-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
| WO-2017031213-A1 | 3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS | Karyopharm Therapeutics Inc. (US) | 2017-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218207-A1 | 3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators | NAMPT, PAK3, PAK5 | PAK4 7/4885HRH3 2253/4885GABRA5 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.